In the absence of a specific therapy, patients with FV-short–related bleeding disorders have been successfully managed with a variety of bypassing agents (factor eight inhibitor bypassing activity, prothrombin complex concentrate, and recombinant FVIIa), often in combination with antifibrinolytics [[73], [74], [75]]. This evidence concerns the gene F5 and hemorrhagic disease.